share_log

NAMSA, InspireMD Announce Strategic Outsourcing Partnership To Accelerate New Product Development; Terms Not Disclosed

NAMSA, InspireMD Announce Strategic Outsourcing Partnership To Accelerate New Product Development; Terms Not Disclosed

NAMSA和InspirreMD宣佈建立戰略外包合作伙伴關係以加快新產品開發;條款未披露
Benzinga Real-time News ·  2022/09/08 09:02

NAMSA, a world-leading MedTech Contract Research Organization (CRO) offering global end-to-end development services, and InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard Embolic Prevention System (EPS) for treatment of carotid artery disease and prevention of stroke, announced today that they have entered into a strategic outsourcing partnership to accelerate medical device development and commercialization.

提供全球端到端開發服務的世界領先的醫療技術合同研究組織NAMSA和用於治療頸動脈疾病和預防中風的CGuard血栓預防系統的開發商InSpireMD公司(納斯達克代碼:NSPR)今天宣佈,他們已經達成戰略外包合作伙伴關係,以加快醫療設備的開發和商業化。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論